Do analysts rate RNAZ or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate RDHL or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, RDHL or ONCO?

Redhill Biopharma has higher earnings, but lower revenue than Onconetix. Redhill Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 14.54 -$430K $1.05 thousand 0.00 Onconetix $735.20K 1.48 -$14.03M $11.40 0.08

Do analysts rate ENSC or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ONCO or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, ONCO or GOVX?

Onconetix has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Onconetix $735.20K 1.48 -$14.03M $11.40 0.08 GeoVax Labs $2.49M 1.66 -$21.47M -$19.12 N/A

Is ONCO or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Onconetix -1,316.28% -101.08% -47.34% GeoVax Labs N/A -709.52% -399.33%

Onconetix (ONCO) Competitors

$0.96 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.97 +0.01 (+1.10%)

As of 07/2/2026 07:59 PM Eastern

Compare

ONCO vs. RNAZ, RDHL, SXTP, ENSC, and GOVX

Should you buy Onconetix stock or one of its competitors? MarketBeat compares Onconetix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Onconetix include TransCode Therapeutics (RNAZ), Redhill Biopharma (RDHL), 60 Degrees Pharmaceuticals (SXTP), Ensysce Biosciences (ENSC), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.

How does Onconetix compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

TransCode Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Onconetix	-1,316.28%	-101.08%	-47.34%

In the previous week, TransCode Therapeutics had 1 more articles in the media than Onconetix. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Onconetix. TransCode Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Onconetix	Neutral

Onconetix has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.9% of Onconetix shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TransCode Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market.

Summary

Onconetix beats TransCode Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Onconetix compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Redhill Biopharma's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

Redhill Biopharma has a beta of 4.98, suggesting that its share price is 398% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, suggesting that its share price is 169% more volatile than the broader market.

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Onconetix	Neutral

Redhill Biopharma has higher earnings, but lower revenue than Onconetix. Redhill Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08

Summary

Redhill Biopharma beats Onconetix on 8 of the 11 factors compared between the two stocks.

How does Onconetix compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, suggesting that its share price is 169% more volatile than the broader market.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

60 Degrees Pharmaceuticals has higher revenue and earnings than Onconetix. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08

60 Degrees Pharmaceuticals has a net margin of -574.91% compared to Onconetix's net margin of -1,316.28%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Onconetix	-1,316.28%	-101.08%	-47.34%

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Onconetix. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Onconetix's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Positive
Onconetix	Neutral

Summary

60 Degrees Pharmaceuticals beats Onconetix on 11 of the 16 factors compared between the two stocks.

How does Onconetix compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Onconetix	Neutral

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ensysce Biosciences has a net margin of -250.39% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Onconetix	-1,316.28%	-101.08%	-47.34%

Ensysce Biosciences has higher revenue and earnings than Onconetix. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.86	-$10.18M	-$3.35	N/A
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ensysce Biosciences has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market.

Summary

Onconetix beats Ensysce Biosciences on 7 of the 11 factors compared between the two stocks.

How does Onconetix compare to GeoVax Labs?

Onconetix (NASDAQ:ONCO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GeoVax Labs had 2 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Onconetix. GeoVax Labs' average media sentiment score of 0.49 beat Onconetix's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Onconetix	Neutral
GeoVax Labs	Neutral

Onconetix has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A

Onconetix has a beta of 2.69, suggesting that its share price is 169% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, suggesting that its share price is 268% more volatile than the broader market.

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
GeoVax Labs	N/A	-709.52%	-399.33%

Summary

GeoVax Labs beats Onconetix on 9 of the 15 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	0.08	21.61	28.02	24.70
Price / Sales	1.48	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.00	8.66	10.96	6.46
Net Income	-$14.03M	$23.81M	$3.57B	$337.01M
7 Day Performance	-2.15%	3.39%	2.12%	1.69%
1 Month Performance	-7.23%	10.81%	5.25%	3.81%
1 Year Performance	-99.59%	62.61%	33.29%	23.90%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.789 of 5 stars	$0.96 flat	N/A	-99.6%	$1.09M	$735.20K	0.08	12	Gap Up
RNAZ TransCode Therapeutics	0.1162 of 5 stars	$4.94 +1.5%	N/A	+7.1%	$4.69M	N/A	N/A	9	News Coverage Short Interest Increase
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.89 -4.3%	N/A	-59.7%	$4.60M	$290K	0.00	210	Short Interest Decrease Gap Down
SXTP 60 Degrees Pharmaceuticals	3.457 of 5 stars	$1.67 -0.6%	$13.85 +729.3%	-82.2%	$4.44M	$1.00M	N/A	3
ENSC Ensysce Biosciences	0.4159 of 5 stars	$0.29 +4.7%	N/A	-87.7%	$4.43M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. RNAZ, RDHL, SXTP, ENSC, and GOVX

How does Onconetix compare to TransCode Therapeutics?

Summary

How does Onconetix compare to Redhill Biopharma?

Summary

How does Onconetix compare to 60 Degrees Pharmaceuticals?

Summary

How does Onconetix compare to Ensysce Biosciences?

Summary

How does Onconetix compare to GeoVax Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. RNAZ, RDHL, SXTP, ENSC, and GOVX

How does Onconetix compare to TransCode Therapeutics?

Is RNAZ or ONCO more profitable?

Does the media favor RNAZ or ONCO?

Which has stronger valuation and earnings, RNAZ or ONCO?

Do analysts rate RNAZ or ONCO?

Do institutionals & insiders have more ownership in RNAZ or ONCO?

Which has more volatility & risk, RNAZ or ONCO?

Summary

How does Onconetix compare to Redhill Biopharma?

Do insiders & institutionals have more ownership in RDHL or ONCO?

Do analysts rate RDHL or ONCO?

Is RDHL or ONCO more profitable?

Which has more volatility and risk, RDHL or ONCO?

Does the media favor RDHL or ONCO?

Which has better earnings & valuation, RDHL or ONCO?

Summary

How does Onconetix compare to 60 Degrees Pharmaceuticals?

Do analysts recommend SXTP or ONCO?

Which has more risk & volatility, SXTP or ONCO?

Do insiders and institutionals have more ownership in SXTP or ONCO?

Which has higher valuation & earnings, SXTP or ONCO?

Is SXTP or ONCO more profitable?

Does the media favor SXTP or ONCO?

Summary

How does Onconetix compare to Ensysce Biosciences?

Does the media prefer ENSC or ONCO?

Do institutionals and insiders hold more shares of ENSC or ONCO?

Is ENSC or ONCO more profitable?

Which has better valuation & earnings, ENSC or ONCO?

Do analysts rate ENSC or ONCO?

Which has more volatility & risk, ENSC or ONCO?

Summary

How does Onconetix compare to GeoVax Labs?

Do insiders & institutionals hold more shares of ONCO or GOVX?

Does the media refer more to ONCO or GOVX?

Which has better valuation & earnings, ONCO or GOVX?

Which has more volatility and risk, ONCO or GOVX?

Do analysts rate ONCO or GOVX?

Is ONCO or GOVX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools